Table 3.

Novel agents inducing HbF

Name	Mechanism	Trial phase, type, NTC#	Primary end points	Status	Results and comments
Decitabine + THU	DNA methyltransferase1 inhibitor	1, single blinded, NCT01685515	AEs grade ≥3	Completed	All SCD genotypes
					Well tolerated; HbF 4%-9% increase and doubling of F cells in higher-dose cohorts; increase in platelet counts noted54
Metformin	FOXO3 inducer	1, open label, NCT02981329	Change in HbF % or Hb	Recruiting	Age 12-40 y
INCB059872	LSD1 inhibitor	1, open label, NCT03132324	Safety and tolerability, HbF levels	Recruiting

Unless otherwise specified, study included only patients with HbSS or HbSβ0.

AE, adverse event.